Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia

C. D. Bloomfield, L. M. Secker-Walker, A. I. Goldman, H. Van Den Berghe, A. de la Chapelle, T. Ruutu, G. Alimena, O. M. Garson, H. M. Golomb, J. D. Rowley, Y. Kaneko, J. Whang-Peng, E. Prigogina, P. Philip, A. A. Sandberg, S. D. Lawler, F. Mitelman

研究成果: 雜誌貢獻文章同行評審

134 引文 斯高帕斯(Scopus)


To evaluate the importance of pretreatment karyotype in predicting long-term outcome in acute lymphoblastic leukemia (ALL), we performed a follow-up study of the 329 patients from the Third International Workshop on Chromosomes in Leukemia. Living patients have now been followed a minimum of 6 years. Patients were divided into ten groups according to pretreatment karyotype: no abnormalities, one of the following structural abnormalities [the Philadelphia chromosome, rearrangements involving 8q24, t(4;11), 14q+, 6q-] or, in the remaining cases, modal number (<46, 46, 47-50, >50). As previously reported for achievement and duration of complete remission, and overall survival, disease-free survival differed significantly (p < 0.001) among chromosome groups for both adults and children. Among children, karyotype was an independent prognostic factor for predicting disease-free survival. Because of the long follow-up, we now have been able to utilize statistical models to estimate the percentage of patients cured, according to karyotype alone and combined with other risk factors. Adults with the highest likelihood of cure (21-33%) were those patients with FAB-L1, a leukocyte count of 50,000/μl or less, and one of the following chromosome groups: greater than 50, 47-50, 6q-, or normal. In children these same characteristics were associated with the highest percentage of cure (58-71% cured). In addition, we identified several groups of children with less than 15% chance of cure who clearly need to be treated as high-risk patients at diagnosis. Future studies of patients who have received risk-adapted therapy based on these chromosome data are needed to determine if more intensive treatment will improve the outlook of patients with cytogenetically unfavorable types of ALL.
頁(從 - 到)171-185
期刊Cancer Genetics and Cytogenetics
出版狀態已發佈 - 7月 15 1989

ASJC Scopus subject areas

  • 分子生物學
  • 遺傳學
  • 癌症研究


深入研究「Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia」主題。共同形成了獨特的指紋。